Target intelligence / Profile preview

Aggregated alpha-synuclein fibrils (site-9 pocket) (aSyn fibrils (site-9))

Target
aSyn fibrils (site-9)
Molecular classification
Amyloid fibril, Protein aggregate, Prion-like protein
01

Overview

Aggregated alpha-synuclein fibrils are the pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and Multiple System Atrophy (MSA). These fibrils are composed of misfolded alpha-synuclein proteins that adopt a cross-beta sheet structure, which is highly stable and neurotoxic (Schweighauser et al., Nature 2020). The site-9 pocket is a specific, high-affinity binding site identified within the structural architecture of these fibrils, particularly in the polymorphs associated with MSA. This pocket is formed by the packing of the non-amyloid component (NAC) region and is a primary target for the development of selective positron emission tomography (PET) tracers like ACI-12589 (Kuebler et al., JNM 2023). By binding to this site, diagnostic agents can distinguish alpha-synuclein aggregates from other amyloidogenic proteins such as tau or amyloid-beta. Furthermore, the site-9 pocket is a focal point for therapeutic strategies aimed at small-molecule inhibition of fibril elongation and seeding, which are key drivers of disease progression in the central nervous system (Smith et al., Nat Rev Drug Discov 2023).

Other names
Alpha-synuclein aggregatesSNCA fibrilsLewy body filamentsSite 9 binding sitePathological alpha-synuclein filamentsMSA-type alpha-synuclein filaments
02

Mechanism of action

High-affinity binding to the site-9 hydrophobic pocket of alpha-synuclein fibrils to facilitate PET imaging or sterically inhibit the recruitment of monomers to the fibril ends.

03

Biological functions

Pathological protein aggregationNeurotoxicityDisruption of synaptic functionInduction of neuroinflammation
04

Disease associations

Parkinson's diseaseMultiple system atrophyDementia with Lewy bodiesPure autonomic failure
05

Safety considerations

Off-target binding to other amyloid proteins (e.g., Tau or Amyloid-beta)Blood-brain barrier permeabilityPotential for stabilizing toxic oligomeric intermediates
06

Interacting drugs

ACI-12589

3 more in the full profile.

07

Biomarkers

Alpha-synuclein PET signalCSF alpha-synuclein seed amplification assay (SAA)pS129 alpha-synuclein levels in skin biopsy

Beyond the preview

Go deeper on Aggregated alpha-synuclein fibrils (site-9 pocket) (aSyn fibrils (site-9)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aggregated alpha-synuclein fibrils (site-9 pocket) (aSyn fibrils (site-9)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call